Accessing sustainable pipeline growth through N1 delivery platform
Transforming Previous R&D Loss into Gold Mine for Drug Development
About N1 Life
N1 Life, Inc. is a biopharma company founded at Stanford in 2019. The company focuses on the early development (preclinical to early clinical) of new therapeutics using its barrier-penetrating delivery platform. The N1 delivery technology enables a fast-path strategy to the clinic and consumer market by maximizing the benefit of known drugs/drug candidates and existing data, and accessing the previously undruggable space.
N1 Life is creating an innovative and sustainable model consisting of therapeutic pipeline, screening service, and consumer product program.
N1 Delivery Platform
N1 Life develops new therapeutic candidates by learning from preclinical and clinical data of existing drugs or drug candidates, and maximizing their advantages through the innovative N1 delivery technology.
Rethink drug development
Rescue drug failures
Reinvestigate existing data
Recover sunk R&D cost